Cardinal Capital Management Inc. Has $27 Million Position in Becton, Dickinson and Company $BDX

Cardinal Capital Management Inc. boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 6.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 178,421 shares of the medical instruments supplier's stock after purchasing an additional 11,039 shares during the quarter. Cardinal Capital Management Inc. owned about 0.06% of Becton, Dickinson and Company worth $27,000,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Auto Owners Insurance Co boosted its position in shares of Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after acquiring an additional 40,528,680 shares during the period. Wellington Management Group LLP raised its stake in Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock worth $979,290,000 after purchasing an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock valued at $769,397,000 after purchasing an additional 4,137,888 shares during the period. Finally, Norges Bank acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $734,321,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BDX shares. Weiss Ratings reiterated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research report on Friday. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. The Goldman Sachs Group dropped their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a report on Wednesday, May 27th. Finally, Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $185.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $181.28 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a market cap of $49.95 billion, a PE ratio of 54.60, a price-to-earnings-growth ratio of 12.66 and a beta of 0.19. The company has a 50 day moving average of $155.80 and a 200-day moving average of $161.85. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.84%. The business had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the firm posted $3.68 earnings per share. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source